Recap: Esperion Therapeutics Q2 Earnings

 

Shares of Esperion Therapeutics ESPR remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share were down 138.66% over the past year to ($1.67), which beat the estimate of ($1.84).

Revenue of $40,659,000 decreased by 80.84% year over year, which missed the estimate of $42,270,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Esperion Therapeutics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Aug 03, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/o2zzweju

Price Action

Company's 52-week high was at $41.48

52-week low: $14.76

Price action over last quarter: down 25.09%

Company Overview

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!